Huang et al. categorized patients into LR, intermediate-risk, and HR based on WBC and platelet levels.11 Zheng grouped patients into standard risk and HR based on WBC count and FLT3-ITD mutations.16 Since FLT3-ITD does not affect APL aggressiveness in adult,25 our study classified patients into LR and HR groups based solely on WBC count for simplicity and feasibility. The gene discussed is FLT3; the disease is acute promyelocytic leukemia.